-- Simcere Pharmaceutical (HKG:2096) received Chinese regulatory approval to begin clinical trials of SIM0613, according to a Hong Kong bourse filing Wednesday.
The injection is intended to treat advanced solid tumors and is licensed to Ipsen Pharma in regions outside Greater China.